My observations are my own and based on my extensive experience conducting clinical trials. I am sure not everyone will agree with my perspective. I have tried my best to present an "objective" review of this very important Trial.
MY SUMMARY:
An antiviral drug which was historically ineffective in all its potential applications through the years but was promoted as a possibility to treat Covid-19 remains very questionable as a primary treatment drug for Covid-19.
___________________________________________________________________________________
OVERVIEW: The US NIAID (Dr. Fauci) published the results this Friday of the “re-purposed” drug Remdesivir clinical trial in the NEJM.
The agency claims the huge Phase 3 trial with 1,063 participants was a success since they felt it shortened recovery time versus the sugar pill placebo (I sincerely hope it did!) from 15 to 11 days.
As I drilled down into the details and numbers I wasn’t quite so sure this drug should be promoted as the US’s “standard of care” for Covid-19 or that NIAID was being specific enough in their comments to afford intelligent national policy decisions.
FINDINGS: This trial was a well designed Phase 3 trial with 8(!) different categories (arms) of patients conditions and more than 1,000 participants of all ages spread across the 8 conditions as best as possible. Plenty of data and details. So what did I find?
In the 3 critical Covid-19 conditions I examined extremely closely: 1) supplemental oxygen, 2) ventilator, and 3) ECMO... it was clear that Remdesivir only significantly helped those on supplemental oxygen.
CRITICALITY: What is the critical takeaway here?
***No (as in very little) marked benefit from remdesivir was found for those who were healthier and didn’t need oxygen or those who were sicker, requiring a ventilator or a heart-lung bypass machine.***
In fact, which shocked me even more, patients on high-flow oxygen or mechanical ventilator/ECMO did modestly better in the placebo group than those taking remdesivir. Can anyone suggest this drug helps Covid-19 seriously ill patients with this type of result versus a sugar pill? I hope not.
Mortality levels? Pretty much the same between the drug and the sugar pill. Certainly not statistically significant or programmatically significant.
OTHER SIMILAR TRIALS: Unfortunately, I believe these findings repeated the findings of the two (2) Chinese clinical trials with this drug which I reported on many, many weeks ago.
Sharon